Large pharma company needed to access reliable epi data for neuroendocrine carcinoma incidence and treatment patterns

Company wanted to avoid relying on syndicated reports, which lack methodological transparency, providing only high-level details that make it difficult to assess data quality and validity

Conducted comprehensive literature search to identify high quality NEC studies

Critically assessed risk of bias and quality of included studies

Analyzed epidemiology data, carefully vetting and comparing study methodologies

Created comparative summary tables documenting diagnosed incidence, prevalence, percent drug treated, progression by line of therapy, etc.

Highlighted key differences across regions and individual studies

Insights from this report informed our client’s forecasting and drove alignment across clinical development and commercial strategy